ABBV-CLS-7262

Generic Name
ABBV-CLS-7262
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C29H37Cl2F2N3NaO12P
CAS Number
-
Unique Ingredient Identifier
BN9FN5629V
Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects

First Posted Date
2024-03-15
Last Posted Date
2024-07-01
Lead Sponsor
Calico Life Sciences LLC
Target Recruit Count
72
Registration Number
NCT06310876
Locations
🇺🇸

AbbVie Clinical Pharmacology Research Unit (ACPRU), Grayslake, Illinois, United States

A Phase 1 Study Assessing the Effect of Food on the Pharmacokinetics of ABBV- CLS-7262

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: ABBV-CLS-7262
First Posted Date
2023-11-24
Last Posted Date
2024-03-08
Lead Sponsor
Calico Life Sciences LLC
Target Recruit Count
18
Registration Number
NCT06145607
Locations
🇺🇸

AbbVie Clinical Pharmacology Research Unit (ACPRU), Grayslake, Illinois, United States

A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: ABBV-CLS-7262
First Posted Date
2023-03-10
Last Posted Date
2023-06-26
Lead Sponsor
Calico Life Sciences LLC
Target Recruit Count
12
Registration Number
NCT05763459
Locations
🇺🇸

AbbVie Clinical Pharmacology Research Unit (ACPRU), Grayslake, Illinois, United States

HEALEY ALS Platform Trial - Master Protocol

First Posted Date
2020-03-05
Last Posted Date
2024-06-27
Lead Sponsor
Merit E. Cudkowicz, MD
Target Recruit Count
1500
Registration Number
NCT04297683
Locations
🇺🇸

Neurology Associates, P.C./Somnos Clinical Research, Lincoln, Nebraska, United States

🇺🇸

Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States

🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

and more 73 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy